Cobimetinib
Back to searchMolecule Structure
Scientific Name
Cobimetinib
Description of the Drug
Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB05239
http://www.drugbank.ca/drugs/DB05239
Brand Name(s)
Cotellic
Company Owner(s)
Genentech Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Dual specificity mitogen-activated protein kinase kinase 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL2964 |
| Dual specificity mitogen-activated protein kinase kinase 1 | SINGLE PROTEIN | INHIBITOR | CHEMBL3587 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL189565 | ||
| PharmGKB | PA166160044 | ||
| DrugBank | DB05239 | ||
| PubChem: Thomson Pharma | 24904580 | ||
| PubChem | 16222096 | ||
| LINCS | LSM-45714 | ||
| Nikkaji | J3.423.737I | ||
| PDBe | EUI | ||
| BindingDB | 50391802 | ||
| EPA CompTox Dashboard | DTXSID60239435 | ||
| DrugCentral | 5046 | ||
| Brenda | 217815 | 217797 | |
| ChemicalBook | CB32551361 | ||
| Guide to Pharmacology | 7626 | ||
| rxnorm | COTELLIC | COBIMETINIB | COBIMETINIB FUMARATE |
| ChEBI | 90851 | ||
| ZINC | ZINC000060325170 |
